4 recruiting, 3 active not recruiting, 2 completed, 1 not yet recruiting. 4 Phase 1, 4 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 3, Completed 1 |
| Phase 2 | 4 | Active not recruiting 1, Completed 1, Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 3 | Active not recruiting 2, Recruiting 1 |
Follow Suzhou Alphamab Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of KN057 Prophylaxis in Patients With Haemophilia A or B KN057 - Hemophilia A or B | Phase 3 | Recruiting | Suzhou Alphamab Co., Ltd. | 70 | 2026-03-13 | 2026-04-22 |
| KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors KN057 - Hemophilia a and B | Phase 2 | Not yet recruiting | Suzhou Alphamab Co., Ltd. | 24 | 2025-09-02 | 2024-12-24 |
| To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients KN060 - End-Stage Renal Disease Requiring Haemodialysis | Phase 1 / Phase 2 | Recruiting | Suzhou Alphamab Co., Ltd. | 12 | 2025-08-22 | 2025-10-01 |
| To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension KN060, 0.9% Sodium Chloride Injection - Hypertension | Phase 1 | Recruiting | Suzhou Alphamab Co., Ltd. | 60 | 2025-08-05 | 2025-09-25 |
| A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight KN069 - Overweight or Obesity | Phase 1 | Recruiting | Suzhou Alphamab Co., Ltd. | 36 | 2024-08-02 | 2025-09-17 |
| Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors KN057 - Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor | Phase 3 | Active not recruiting | Suzhou Alphamab Co., Ltd. | 125 | 2024-04-01 | 2025-09-17 |
| Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors KN057 - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 3 | Active not recruiting | Suzhou Alphamab Co., Ltd. | 53 | 2024-01-09 | 2025-09-17 |
| Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty Enoxaparin, KN060 Low, KN060 Middle - Knee Arthroplasty, Total | Phase 2 | Active not recruiting | Suzhou Alphamab Co., Ltd. | 241 | 2023-12-20 | 2025-09-17 |
| A Study to Evaluate Effects of KN056 in Healthy Participants KN056 (0.1mg), KN056 (0.3mg), KN056 (1.0mg) - Type 2 Diabetes | Phase 1 | Completed | Suzhou Alphamab Co., Ltd. | 46 | 2022-08-09 | 2024-12-30 |
| KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia KN057 doseⅠ, KN057 dose Ⅱ, KN057 dose Ⅲ - Hemophilia | Phase 2 | Completed | Suzhou Alphamab Co., Ltd. | 24 | 2022-07-07 | 2024-12-30 |
Hemophilia A (3) · Diabetes Mellitus, Type 2 (1) · Essential Hypertension (1) · Hypertension (1) · Obesity (1) · Overweight (1)
Enoxaparin (1) · Sodium Chloride (1)
China (8) · New Zealand (1)
Changcheng Zheng, Doctor (4) · Hu Zhou, Doctor (4) · Renchi Yang, Doctor (4) · Jing Sun, Doctor (3) · Xielan Zhao, Doctor (3) · Yanping Song, Doctor (3) · Zeping Zhou, Doctor (3) · Ziqiang Yu, Doctor (3) · Chenghao Jin, Doctor (2) · Jingyu Yan, Doctor (2) · Lili Chen, Doctor (2) · Rong Zhou, Doctor (2) · Runhui Wu, Doctor (2) · Shu Chen, Doctor (2) · Sujun Gao, Doctor (2)